Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
May 07 2014 - 9:00AM
Marketwired
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big
Pharma Heading Into Late Phase Trials
NEW YORK, NY--(Marketwired - May 7, 2014) - Nuvilex, Inc.'s
(OTCQB: NVLX) advanced pancreatic cancer treatment first
outperformed historical data presented by the NYSE's Eli Lilly and
its FDA approved pancreatic cancer drug Gemzar®, then it was
NASDAQ's Celgene and its recently FDA approved treatment of
Abraxane® plus gemcitabine, and now the latest treatment that
Nuvilex's Cell-in-a-Box® combined with the anticancer drug
ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals
and its treatment, the combination of MM-398 with 5-fluorouracil
(5-FU) and leucovorin.
Between these three biopharmaceutical firms, each has FDA
approval or is about to face the FDA seeking approval for an
advanced pancreatic cancer treatment. They also represent 3
separate treatments that Nuvilex's Cell-in-a-Box®/ifosfamide
combination has produced better data than in two successfully
completed Phase I/II clinical trials.
Merrimack Pharmaceuticals announced last week that its
combination of MM-398 with 5-fluorouracil and leucovorin achieved
an overall survival of 6.1 months in the company's Phase 3 clinical
trials conducted in patients with metastatic pancreatic cancer who
previously received gemcitabine-based therapy.
This announcement is great news for pancreatic cancer patients
and the Pancreatic Cancer Action Network whose CEO Julie Fleshman
said of the results, "The Pancreatic Cancer Action Network's goal
is to double pancreatic cancer survival by 2020. The positive
results of this trial demonstrate progress toward that goal in a
disease for which additional treatment options are urgently needed
to improve patient outcomes."
With these latest results, the stage is set for Nuvilex in the
pancreatic cancer arena as they prepare to begin late phase
clinical trials with a treatment that may just get the Pancreatic
Cancer Action Network to its goal sooner than 2020. Results
from previous clinical trials using Nuvilex's
Cell-in-a-Box®/ifosfamide treatment included a median survival time
of 11 months versus 8.5 months for patients treated with a
combination of Abraxane plus gemcitabine versus 6.7 months for
gemcitabine alone. So, one thing is for sure Nuvilex can
compete with big pharma, and in the end, it may top them all.
About Stock Market Media Group SMMG is a Research and Content
Development IR firm offering a platform for corporate stories to
unfold in the media with Reports, Interviews and Articles. SMMG is
compensated for Nuvilex articles, reports, and interviews by a
third party who reserves the right to buy, sell or remain neutral
on securities after the publication of this article. SMMG has
received total compensation of $81,695 for content related to
Nuvilex. Additionally, a principal at SMMG currently owns 200,000
total shares of Nuvilex issued by the company through a consulting
agreement which has since ended for work unrelated to content
development. The shares have been held for the requisite period
under Rule 144 as of April 30, 2013, and are eligible to be sold
immediately without further notice. For more information:
www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact